Ocugen to Present at 2024 BIO International Convention

MALVERN, Pa., May 29, 2024 -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company specializing in innovative gene and cell therapies and vaccines, announced its participation in the 2024 BIO International Convention held in San Diego, CA from June 3-6, 2024.

At the convention, Ocugen’s executive team plans to meet with potential collaborators and pharmaceutical leaders to investigate opportunities for its diverse pipeline, which aims to address significant medical needs. Their focus includes pioneering ophthalmic modifier gene therapy and regenerative cell therapy platforms.

Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, expressed enthusiasm about the event. "We are thrilled to return to BIO this year to present the major clinical and strategic advances we’ve made," he said. "BIO provides a crucial platform for forming partnerships that will advance our innovative therapies and enhance shareholder value. We look forward to engaging with the esteemed industry professionals present."

Ocugen’s modifier gene therapy platform has hit several key milestones recently. Notably, the OCU400 Phase 3 liMeLiGhT clinical trial for retinitis pigmentosa—impacting around 300,000 individuals in the U.S. and Europe—has commenced. Furthermore, dosing for Cohort 2 has been completed in both the OCU410 Phase 1/2 ArMaDa clinical trial targeting geographic atrophy due to dry age-related macular degeneration (affecting 2-3 million individuals in the U.S. and Europe) and the OCU410ST Phase 1/2 GARDian trial for Stargardt disease, which affects approximately 100,000 people in the same regions.

NeoCart® represents Ocugen’s advanced Phase 3-ready regenerative cell therapy candidate. This therapy uses an enhanced autologous cartilage repair method and has shown promising results by fully restoring cartilage in some patients within six months. NeoCart is unique as it employs a 3D scaffold and novel bioreactor to simulate compressive stress and improve cartilage cell differentiation. Recently, Ocugen completed its cutting-edge cell and gene therapy manufacturing facility.

Ocugen’s presentation at the BIO 2024 International Convention is scheduled as follows:
- Event: BIO 2024 International Convention
- Date: Monday, June 3, 2024
- Time: 2:15 p.m. PT
- Location: Presentation Theater 1 - Hall A - Exhibition Hall, San Diego Convention Center
- Presenter: Dr. Shankar Musunuri, Chairman, CEO, and Co-founder

Attendees are invited to visit Ocugen at Booth #3945 to learn more about the company’s clinical programs and their potential impact on patients.

About Ocugen, Inc.
Ocugen, Inc. is dedicated to discovering, developing, and commercializing novel gene and cell therapies and vaccines aimed at improving global health. The company is committed to making a significant impact on patient lives through innovative approaches, leveraging unique intellectual and human resources. Ocugen’s breakthrough modifier gene therapy platform holds the potential to treat multiple retinal diseases with a single product. The company is also advancing research in infectious diseases to support public health and orthopedic diseases to meet unmet medical needs.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!